APO-NEBIVOLOL TABLET
Land: Canada
Språk: engelsk
Kilde: Health Canada
Preparatomtale
(SPC)
23-09-2019
Noen dokumenter for dette produktet er ikke tilgjengelig for øyeblikket, du kan sende en forespørsel til kundeservicen vår, og vi vil varsle deg så snart vi kan få dem.
Send forespørsel.
Send forespørsel.
Aktiv ingrediens:
NEBIVOLOL (NEBIVOLOL HYDROCHLORIDE)
Tilgjengelig fra:
APOTEX INC
ATC-kode:
C07AB12
INN (International Name):
NEBIVOLOL
Dosering :
5MG
Legemiddelform:
TABLET
Sammensetning:
NEBIVOLOL (NEBIVOLOL HYDROCHLORIDE) 5MG
Administreringsrute:
ORAL
Enheter i pakken:
100
Resept typen:
Prescription
Terapeutisk område:
BETA-ADRENERGIC BLOCKING AGENTS
Produkt oppsummering:
Active ingredient group (AIG) number: 0153531002; AHFS:
Autorisasjon status:
APPROVED
Autorisasjon dato:
2020-12-22
Preparatomtale
Page 1 of 34
PRODUCT MONOGRAPH
PR
APO-NEBIVOLOL
Nebivolol Tablets
2.5 mg, 5 mg and 20 mg Nebivolol
(as nebivolol hydrochloride)
Antihypertensive Agent
APOTEX INC.
Date of Preparation:
150 Signet Drive
September 23, 2019
Toronto, Ontario
M9L 1T9
Submission Control No: 223530
Page 2 of 34
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................................
3
SUMMARY PRODUCT INFORMATION
.......................................................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................................................
3
CONTRAINDICATIONS
..................................................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................................................
4
ADVERSE REACTIONS
..................................................................................................................................
7
DRUG INTERACTIONS
.................................................................................................................................
11
DOSAGE AND ADMINISTRATION
.............................................................................................................
13
OVERDOSAGE
...............................................................................................................................................
14
ACTION AND CLINICAL PHARMACOLOGY
...........................................................................................
15
STORAGE AND
STABILITY.........................................................................................................................
18
SPECIAL HANDLING INSTRUCTIONS
......................................................................................................
18
DOSAGE FORMS, COMPOSITION AND PACKAGING
..
Les hele dokumentet
